{"title":"New ways of patient participation in clinical and translational cancer research.","authors":"Wiebke Kragl, Jonathan P Sleeman, Jörg Haier","doi":"10.1007/s10585-026-10450-w","DOIUrl":"https://doi.org/10.1007/s10585-026-10450-w","url":null,"abstract":"","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jawad Fares, Deepak Kanojia, Edgar Petrosyan, Alex L Tobias, Rafal Chojak, Atique U Ahmed, Irina V Balyasnikova, Maciej S Lesniak
{"title":"Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis.","authors":"Jawad Fares, Deepak Kanojia, Edgar Petrosyan, Alex L Tobias, Rafal Chojak, Atique U Ahmed, Irina V Balyasnikova, Maciej S Lesniak","doi":"10.1007/s10585-026-10449-3","DOIUrl":"10.1007/s10585-026-10449-3","url":null,"abstract":"<p><p>Cell-based therapies can formulate and deliver biologics within the brain, but their development has relied largely on survival outcomes that do not distinguish inadequate payload potency from inadequate tumor distribution. We evaluated intratumoral coverage as a quantitative endpoint for cell-mediated delivery using neural stem cells (NSCs) engineered to secrete an anti-HER2 antibody in breast cancer brain metastasis. Intracranial HER2-positive BT474Br tumors received a single dose of 5 × 10<sup>5</sup> anti-HER2 antibody-secreting NSCs. Secreted human IgG was reconstructed across consecutive 10-µm sections spanning the entire tumor depth, and therapeutic activity of the same cell dose administered once was assessed in an independent survival experiment. A single NSC dose produced a mean section-level antibody coverage of 60.6%; coverage was ≥ 25% in 96.8% of sections and ≥ 50% in 74.2%. Coverage was greatest in the tumor core and declined toward both poles, a pattern consistent with carrier-cell localization limiting therapeutic reach. The same dose extended median survival from 67 days with vector-control NSCs to 73.5 days (P = 0.0009) and increased restricted mean survival by 10.8 days. These data provide an initial spatial benchmark for a therapeutically active dose and establish tumor coverage as a mechanistically informative endpoint for intracranial cell-based delivery.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13751723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J Jonsson, A Ling, J Axelsson, M Lundin, P Vermeulen, K Riklund, H Nyström
{"title":"Preoperative classification of histopathological growth patterns in colorectal liver metastases using prospective 18 F-FDG PET/CT.","authors":"J Jonsson, A Ling, J Axelsson, M Lundin, P Vermeulen, K Riklund, H Nyström","doi":"10.1007/s10585-026-10441-x","DOIUrl":"10.1007/s10585-026-10441-x","url":null,"abstract":"<p><p>Colorectal liver metastases (CLM) exhibit distinct histopathological growth patterns (HGPs) at the metastasis-liver interface, clinically relevant for prognosis and potential predictive value. This study investigates the feasibility of using Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (<sup>18</sup>F-FDG PET/CT) to preoperatively classify HGPs in CLM and secondly investigate PET parameters as prognostic markers for overall survival (OS). In a prospective study at Umeå University Hospital (June 2013-December 2017), 78 patients with resectable CLM underwent contrast-enhanced liver MRI and <sup>18</sup>F-FDG PET/CT imaging. HGP classification was performed on tissue sections according to 2017 international guidelines. PET features (SUV<sub>mean</sub> [standardised uptake value], SUV<sub>max</sub>, metabolic tumour volume [MTV] and first-order texture metrics) were analysed to distinguish encapsulating (eHGP) from replacement (rHGP) patterns. In pretreated patients, multivariate logistic regression including both metabolic and texture parameters identified significant associations for parameters from the fixed level threshold algorithm (VuePoint Sharp IR) with small odds ratios. Overall, PET parameters showed limited ability to discriminate between eHGP and rHGP. OS was superior with eHGP versus rHGP (log-rank p = 0.045). In chemonaïve patients, SUV-based metrics showed unadjusted exploratory associations with OS after liver surgery, varying by reconstruction/delineation and were not significant after correction for multiple testing. FDG-PET-derived parameters were not reliably associated with HGP and did not support non-invasive HGP prediction in this cohort. eHGP was associated with superior survival, underscoring the value of HGP assessment for prognostication while alternative non-invasive biomarkers remain to be identified.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13743569/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149370031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jae-Uk Jeong, Gyu Sang Yoo, Jong Hoon Lee, Yong Chan Ahn, Chai Hong Rim, Eui Kyu Chie, Ah Ram Chang
{"title":"Oncologic efficacy and safety of stereotactic body radiotherapy for oligometastatic non-small cell lung cancer: a systemic meta-analysis.","authors":"Jae-Uk Jeong, Gyu Sang Yoo, Jong Hoon Lee, Yong Chan Ahn, Chai Hong Rim, Eui Kyu Chie, Ah Ram Chang","doi":"10.1007/s10585-026-10445-7","DOIUrl":"10.1007/s10585-026-10445-7","url":null,"abstract":"<p><strong>Purpose: </strong>With the increasing clinical interest on local consolidative therapies for oligometastasis (OM), stereotactic body radiotherapy (SBRT) has emerged as a definitive and optimal treatment modality. This study stratifies oligoprogressive (OPD), oligorecurrent (ORD), and oligopersistent (OPSD) states-alongside single-lesion subgroup analyses-to systematically evaluate the efficacy and safety of SBRT for oligometastatic NSCLC.</p><p><strong>Materials and methods: </strong>This meta-analysis was conducted utilizing the Pubmed, Embase and Medline. The quantitative synthesis included 18 eligible studies comprising a total of 1,105 patients. The clinical endpoints assessed were overall survival (OS), progression-free survival (PFS), local control (LC), and the incidence of severe (grade 3 or higher) treatment-related toxicities.</p><p><strong>Results: </strong>The pooled estimates demonstrated robust oncological outcomes; 2-year OS of 60.0% (95% CI, 50.4-68.8%), 1-year PFS of 65.8% (95% CI, 52.7-76.8%), and 2-year LC rate of 74.2% (95% CI, 63.9-82.4%). The incidence of severe toxicities (grade ≥ 3) was 4.5%, predominantly manifesting as radiation pneumonitis and esophagitis. Subgroup analyses revealed that a higher prevalence of single-metastatic lesions (> 59%) exhibited a borderline positive trend toward superior 2-year OS (67.5% vs. 47.8%, p = 0.069).</p><p><strong>Conclusion: </strong>This meta-analysis indicates that SBRT yields favorable treatment outcomes for patients with oligometastatic NSCLC with manageable toxicities. When anatomically feasible, delivering an ablative dose-100 Gy<sub>10</sub> in biologically effective dose-is recommended. Furthermore, tailoring SBRT strategies by oligometastatic subtype-upfront radical SBRT for synchronous disease/ORD and salvage SBRT for OPSD/OPD-is essential to maximize the treatment efficacy.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular, histopathological, and clinical risk factors for overall metastatic disease and brain metastases in surgically resected stage I-III lung cancer.","authors":"Anne Pernille Harlem Dyrbekk, Pål Suhrke, Marianne Odnakk Ludahl, Nermin Zecic, Joakim Oliu Moe, Inger Johanne Zwicky Eide, Marius Lund-Iversen, Odd Terje Brustugun","doi":"10.1007/s10585-026-10444-8","DOIUrl":"10.1007/s10585-026-10444-8","url":null,"abstract":"<p><p>Lung cancer remains a major cause of cancer-related mortality, including among patients diagnosed with potentially curable disease. Current decisions regarding perioperative treatment and follow-up rely on a limited number of established prognostic factors. Further knowledge is needed regarding the clinical, histopathological, and molecular factors associated with subsequent metastatic disease, particularly brain metastasis (BM), which is associated with poor prognosis. We investigated these factors in a large cohort of patients with surgically resected stage I-III lung cancer followed for more than five years. BM was associated with higher pathological tumour and lymph-node stage and younger age at surgery. Lung adenocarcinoma was associated with a higher risk of BM than lung squamous cell carcinoma. Several molecular alterations were associated with metastatic disease or BM, including KRAS mutations in lung adenocarcinoma and NFE2L2 mutations in lung squamous cell carcinoma. Additional associations involving specific EGFR and KRAS mutation subtypes and rarer alterations were observed, but were based on small numbers of cases and should be considered exploratory. Several of the associated genes are involved in the RAS/MAPK, PI3K/AKT/mTOR, or NRF2-related pathways. However, pathway activation and causality could not be established in this observational study. These findings support further investigation of clinical, histopathological, and molecular factors associated with metastatic progression after surgical resection. Validation in larger, independent, stage-stratified and contemporary cohorts with comprehensive treatment data is required before the identified molecular alterations can be considered for clinical risk stratification or surveillance.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13694483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yara Alswaiti, Ghena Shahwan, Bakr Alhayek, Sara Absi, Ahmad Alzyoud, Dua'a Kanaan, Badr Nawar, Mohamad Mahmoud Whdan, Enrique Gutierrez-Valencia, Ayah Erjan
{"title":"PD-1/ PD-l1 Inhibitors and Stereotactic Radiosurgery for Brain Metastases: a systematic review and meta-analysis.","authors":"Yara Alswaiti, Ghena Shahwan, Bakr Alhayek, Sara Absi, Ahmad Alzyoud, Dua'a Kanaan, Badr Nawar, Mohamad Mahmoud Whdan, Enrique Gutierrez-Valencia, Ayah Erjan","doi":"10.1007/s10585-026-10439-5","DOIUrl":"10.1007/s10585-026-10439-5","url":null,"abstract":"<p><strong>Purpose: </strong>Stereotactic radiosurgery (SRS) is the treatment of choice for limited brain metastases (BM), and its combination with PD-1/PD-L1 inhibitors is hypothesized to offer synergistic therapeutic benefits. However, there are concerns regarding augmented risk of radiation-induced brain necrosis (RIBN). This systematic review and meta-analysis evaluate the efficacy and toxicity profile of PD-1/PD-L1 inhibitors combined with SRS or fractionated stereotactic radiotherapy (FSRT).</p><p><strong>Methods: </strong>Four databases were screened, Embase, Web of Science, PubMed and Scopus from inception to November 2025. Primary outcomes were overall survival (OS), extracranial and distant intracranial progression free survival (PFS), and local control (LC). A subgroup analysis was performed based on the primary metastasis origin and radiotherapy treatment modalities. We extracted RIBN events and grade ≥ 3 neurological events. A single-arm meta-analysis was performed using the random-effects modeling. This review protocol was registered on November 2025 on PROSPERO (ID CRD420251171879).</p><p><strong>Results: </strong>Thirty-four studies were included, published between 2016 and 2025 comprising 2,587 patients with BM. The pooled one-year OS was 65% (95% CI 60-69). Patients with BM from Non-Small Cell Lung Cancer (NSCLC) had one-year OS (68%) while melanoma BM had OS (61%). LC and distant intracranial PFS at one year were 87% (95% CI 79-92) and 40.23% (95% CI 17.99-62.47), respectively. The cumulative incidence (CI) of grade 3 RIBN was 5% (95% CI 3-8), and grade ≥ 3 neurological events occurred in 7% (95% CI 4-13). No statistically significant difference in RIBN rates was found between melanoma and NSCLC primaries subgroup.</p><p><strong>Conclusion: </strong>The combination of SRS/FSRT with PD-1/PD-L1 inhibitors is associated with favorable intracranial PFS and LC and a tolerable toxicity profile, with relatively lower rates of grade 3 RIBN. These findings support the feasibility of this combined modality in the immunotherapy era. However, definitive conclusions regarding the incremental risk of RIBN require future prospective trials.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jheremy S Reyes, Constantinos G Hadjipanayis, Ajay Niranjan
{"title":"THINKERS-X: multisequence MRI radiomics in a mixture-of-experts model for outcome prediction and exploratory dose-scenario evaluation in lung cancer brain metastases treated with radiosurgery.","authors":"Jheremy S Reyes, Constantinos G Hadjipanayis, Ajay Niranjan","doi":"10.1007/s10585-026-10443-9","DOIUrl":"10.1007/s10585-026-10443-9","url":null,"abstract":"<p><p>We developed THINKERS-X: Lung, the eXtended multimodal evolution of THINKERS-Lung, to determine whether multisequence MRI radiomics provides incremental value for lesion-specific outcome prediction and exploratory dose-scenario evaluation after Gamma Knife radiosurgery (GKRS) for lung cancer brain metastases. We performed a retrospective single-center study of 767 patients with 3,728 lung cancer brain metastases treated with GKRS. THINKERS-X preserved the original mixture-of-experts and discrete-time survival architecture while adding a dedicated computational neuroradiology expert. Approximately 2,400 radiomic features per metastasis were extracted from pretreatment FSPGR/T1-weighted postcontrast, T2-weighted, and SWAN MRI. Validation used patient-grouped 5-fold cross-validation and a completely closed patient-grouped internal holdout cohort. In grouped cross-validation, THINKERS-X achieved a mean AUC<sub>12</sub> of 0.919 ± 0.021 versus 0.876 for THINKERS-Lung (paired difference, 0.043; 95% CI 0.026-0.061; p < 0.001). In the internal holdout cohort, AUC<sub>12</sub> improved from 0.863 to 0.929 (95% CI 0.895-0.958), with a paired difference of 0.066 (95% CI 0.031-0.101; p < 0.001). Mean absolute error decreased from 1.26 to 0.84 months. The calibrated Brier score was 0.039, calibration slope 0.94, and intercept 0.04. Radiomics altered model-derived dose-response profiles in 30.0% of metastases and the model-ranked candidate dose in 23.9%. THINKERS-X improved lesion-specific longitudinal prediction, temporal accuracy, and probabilistic calibration beyond THINKERS-Lung while materially altering exploratory dose-scenario evaluation in a subset of metastases. External multicenter and prospective validation are required before clinical implementation.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Surgical resection versus stereotactic body radiotherapy for oligometastatic breast cancer to the liver.","authors":"Lianjie Niu, Lixu Zhu, Qiang Zhang, Yongtao Bai, Qigen Fang, Xianfu Sun, Wenzhi Guo","doi":"10.1007/s10585-026-10436-8","DOIUrl":"10.1007/s10585-026-10436-8","url":null,"abstract":"<p><p>Comparative evidence for hepatic resection and stereotactic body radiotherapy (SBRT) in breast cancer liver oligometastases remains limited. We compared survival, progression, and recovery after these treatments. This three-center retrospective study included adults with breast cancer and ≤ 3 liver metastases undergoing hepatic resection or SBRT between 2010 and 2023. Patients with uncontrolled extrahepatic disease were excluded. Propensity score matching generated 1:1 treatment pairs. Overall survival (OS) was the primary endpoint. Adjusted Cox models evaluated OS and progression-free survival (PFS); progression outcomes were analyzed with death as a competing event. Among 1,055 eligible patients, 708 were matched (354 per group). During a median follow-up of 54.8 months, 432 deaths occurred. Median OS was 48.3 months after surgery and 38.8 months after SBRT (adjusted hazard ratio [HR] for SBRT versus surgery, 1.24; 95% confidence interval [CI], 1.02-1.50). Median PFS was 21.8 and 19.7 months, respectively (adjusted HR, 1.13; 95% CI, 0.96-1.33). The 24 month cumulative incidence of treated-site local failure was 7.1% versus 6.5% (adjusted subdistribution HR, 1.12; 95% CI, 0.75-1.68). Median hospital stay was 8 versus 1 day; among patients restarting systemic therapy, median restart intervals were 45 versus 18 days. The OS association became less precise in analyses restricted to R0 resection or liver-only disease. Resection was associated with longer OS, while SBRT was associated with shorter hospitalization and treatment interruption. Uncertain differences in PFS and local failure do not establish equivalence. Residual confounding and treatment heterogeneity limit causal interpretation and warrant prospective comparative evaluation.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13676576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qing-Xiang Wang, Li-Ying Chen, San-Gang Wu, Juan Zhou
{"title":"Brachytherapy-based local radiotherapy improves survival in newly diagnosed metastatic cervical cancer.","authors":"Qing-Xiang Wang, Li-Ying Chen, San-Gang Wu, Juan Zhou","doi":"10.1007/s10585-026-10438-6","DOIUrl":"10.1007/s10585-026-10438-6","url":null,"abstract":"<p><p>To explore if adding local radiotherapy to systemic treatment could enhance the survival of newly-diagnosed stage IVB cervical cancer (CC) patients and compare the impact of different radiotherapy strategies on survival. We included patients diagnosed from 2004 to 2022. Local radiotherapy strategies included external beam radiotherapy (EBRT) and/or brachytherapy (BT). Multivariable Cox regression models were used to assess the link between treatment modality and survival. A total of 4257 patients were involved, all receiving chemotherapy. There were 1280 (30.1%), 2,089 (49.1%), 759 (17.8%), and 129 (3.0%) patients who received chemotherapy alone, chemotherapy plus EBRT, chemotherapy plus EBRT and BT, and chemotherapy plus BT. Using the chemotherapy plus EBRT and BT group as a reference, those on chemotherapy alone had a higher risk of death (cancer-specific survival [CSS]: hazard ratio [HR] 2.037, P < 0.001; overall survival [OS]: HR of 1.992, P < 0.001). Similarly, chemotherapy plus EBRT patients also had an increased risk (CSS: HR 1.576, P < 0.001; OS: HR 1.582, P < 0.001). However, there were no significant differences in CSS (HR 1.082, P = 0.504) and OS (HR 1.083, P = 0.476) between the chemotherapy plus BT group and the reference group. Sensitivity analyses indicated that chemotherapy plus BT and chemotherapy plus EBRT and BT improved survival across subgroups. Our study reveals that adding any form of radiotherapy to chemotherapy for stage IVB CC patients improves survival. BT, alone or combined with EBRT, offers the best outcomes, while EBRT alone has a limited advantage over chemotherapy alone. BT-based local treatment may serve as an effective local treatment option for stage IVB CC.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Effectiveness of local ablative therapy combined with first-line tyrosine kinase inhibitors in epidermal growth factor receptor-mutated oligometastatic non-small cell lung cancer: a systematic review and meta-analysis.","authors":"Rahul Bisht, Arusha Desai, Anjali Bhardwaj, Esteban Marcelo Mogrovejo Carrión, Sidharth Misra, Andela Malaj","doi":"10.1007/s10585-026-10437-7","DOIUrl":"10.1007/s10585-026-10437-7","url":null,"abstract":"<p><p>Epidermal Growth Factor Receptor (EGFR) mutations are a significant driver of NSCLC. Although EGFR-Tyrosine Kinase Inhibitors (TKIs) improve outcomes, the development of resistance limits the survival advantages. Local Ablative Therapy (LAT), particularly radiotherapy, may further enhance outcomes in oligometastatic NSCLC, but its benefit remains uncertain. This meta-analysis evaluates the efficacy of LAT with TKI vs. TKI alone. We systematically searched PubMed, Embase, Web of Science, and Cochrane from inception to May 2025 for studies comparing TKI + LAT versus TKI alone, in patients with EGFR-mutated oligometastatic NSCLC. PRISMA guidelines were followed. Outcomes included overall survival (OS), progression-free survival (PFS), and treatment related adverse effects. We pooled hazard ratios (HR) and risk ratios (RR) with a 95% confidence interval (CI) using a random effects model. Statistical Analysis was performed using R software (version 4.4.2). We included 9 studies with 1077 patients, of whom 525 (48.7%) belonged to the TKI + LAT group. Mean follow-up duration was 29.3 months. Patients receiving TKI + LAT had a significantly longer OS (HR 0.50; 95% CI 0.42-0.59; p < 0.001) and PFS (HR 0.44; 95% CI 0.34-0.58; p < 0.001) versus TKI alone. The toxicity risk was not statistically different between the arms, suggesting that LAT did not significantly increase adverse effects. LAT combined with TKI is associated with improved survival in selected patients with EGFR-mutated oligometastatic NSCLC, particularly when delivered as consolidation therapy, with an acceptable safety profile.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"43 6","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}